TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16061593
Drug: L-aspartic acid
Normalized name: L-Aspartic Acid
DrugBank: Aspartic acid (DB00128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-aspartic acid (6 doses per day, 5 mL per dose)
Study: 16061593
Drug: Enzymatically hydrolyzed
Normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatically hydrolyzed casein (EHC) (6 doses per day, 5 mL per dose)
Study: 16061593
Drug: Whey/casein (W/C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey/casein (W/C) (6 doses per day, 5 mL per dose)
Study: 16061593
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no beta-glucuronidase inhibitors)
Study: 1726009
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of lacidipine
Study: 30526230
Drug: Riluzole 50
Normalized name: riluzole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole 50 mg twice daily for 12 weeks
Study: 27775818
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice a day
Study: 24470753
Drug: Itopride 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 150 mg ER once daily under fasting conditions
Study: 24470753
Drug: Itopride 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 50 mg IR three times daily in fasting state
Study: 24470753
Drug: Itopride 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 150 mg ER once daily under fed conditions
Study: 22392817
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of interleukin-6 (IL-6) soluble receptor (SR)
Study: 17627164
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg daily for 4 weeks, then 20 mg as needed 2-3 hours before sexual activity for 4 months)
Study: 17627164
Drug: Fluoxetine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine combined with sildenafil (50 mg as needed 1 hour before sexual activity for 4 months)
Study: 15855258
Drug: 17beta‐estradiol (E2;
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol (E2; 2 mg, followed by 4 mg)
Study: 15855258
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg, followed by 120 mg)
Study: 11339909
Drug: 2% vaginal
Normalized name: XACIATO 2% Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% vaginal clindamycin cream for 7 days
Study: 11339909
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo cream for 7 days
Study: 10374456
Drug: Twice-daily theophylline
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily theophylline dosing (TD)
Study: 10374456
Drug: Once-daily theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily theophylline dosing (OD)
Study: 30166366
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose alone or combined with maternal holding
Study: 30166366
Drug: Maternal-infant relationship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal-infant relationship (combined with oral glucose and breastfeeding)
Study: 24286965
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring (subcutaneous continuous monitoring system)
Study: 12905095
Drug: 175 g
Normalized name: ALCOHOL 14.175 g in 10 / BENZALKONIUM CHLORIDE 0.042 g in 10 / DIDECYLDIMONIUM CHLORIDE 0.0567 g in 10 TOPICAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 g of CHO (HIGH)
Study: 12905095
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of CHO (LOW)
Study: 10711610
Drug: Systemic ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic ofloxacin therapy (2x200 mg/d for 5 days) as adjunct to flap surgery
Study: 1294304
Drug: Oral sugar
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sugar clearance
Study: 1294304
Drug: Long oral
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long oral clearance time
Study: 7040955
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside intravenous infusion
Study: 7040955
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment and infusion of 5% glucose (Control)
Study: 22258156
Drug: bihemispheric tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: bihemispheric tDCS and simultaneous occupational/physical therapy during the first 5-day period
Study: 22258156
Drug: bihemispheric tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: bihemispheric tDCS and simultaneous occupational/physical therapy during the second 5-day period
Study: 22258156
Drug: bihemispheric tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: bihemispheric tDCS and simultaneous occupational/physical therapy over two periods
Study: 17237312
Drug: Lean red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean red meat intake (approximately 200 g/d)
Study: 10368879
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=6) - no drug treatment, only exercise training
Study: 10368879
Drug: Pretreatment group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment group (n=6) - previously treated with fluvastatin 20 mg/day
Study: 10368879
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n=6) - received fluvastatin 20 mg/day during training
Study: 9050100
Drug: 4% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lignocaine solution
Study: 1908385
Drug: Buccal nitroglycerin
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal nitroglycerin
Study: 7046434
Drug: Combined hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hydrochlorothiazide (25 to 50 mg twice a day) and furosemide (increased doses of 320 to 480 mg/day)
Study: 7046434
Drug: Furosemide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (160 to 240 mg/day)
Study: 18456649
Drug: Ivermectin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (24 mg)
Study: 8889399
Drug: Enhanced Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Intervention (EI) - SI plus additional educational sessions stressing responsible drug use, including active referral in some cities.
Study: 8889399
Drug: Treatment (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (both SI and EI) compared to other interventions.
Study: 1686817
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) treatment
Study: 31092172
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs) injection
Study: 31092172
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical therapy (anti-TNF agents) with setons and additional surgical techniques
Study: 29223955
Drug: Perioperative atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative atorvastatin treatment
Study: 29223955
Drug: Increasing long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing long-term statin dose
Study: 17724088
Drug: Ciprofloxacin PR
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin PR (500 mg)
Study: 17724088
Drug: Warfarin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (7.5 mg)
Study: 17724088
Drug: Warfarin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (7.5 mg) + Ciprofloxacin PR (500 mg)
Study: 15339496
Drug: Kuhuang Injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuhuang Injection, Shenmai Injection, Huangqi Liquid (treatment group)
Study: 15339496
Drug: Ribarvirin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribarvirin and Ganlixin Injection (control group)
Study: 8025391
Drug: Cow's milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk-based formula with 4 mg of iron/l
Study: 8025391
Drug: Cow's milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk-based formula with 7 mg of iron/l
Study: 8025391
Drug: Cow's milk-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk-based formula with selenium (10 micrograms/l)
Study: 27871275
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg once daily)
Study: 10999810
Drug: DHEA 25
Normalized name: GNP DHEA 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 25 mg
Study: 9118514
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg UID
Study: 9118514
Drug: Treatment-induced changes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-induced changes in average daytime and nighttime BPs
Study: 8419392
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of cefotiam, given twelve hours apart
Study: 3025151
Drug: Various formulations
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various formulations of acyclovir
Study: 25867608
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (20 mg of esomeprazole, 1 g of amoxicillin, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily for 10 days)
Study: 25867608
Drug: Hybrid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapy (5-day dual therapy of 20 mg of esomeprazole and 1 g of amoxicillin, twice daily followed by 5-day quadruple therapy of 20 mg of esomeprazole, 1 g of amoxicillin, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily)
Study: 20854305
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac sodium solution with DMSO
Study: 20854305
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium gel
Study: 19242406
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg memantine (in rats)
Study: 19242406
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg memantine (in rats)
Study: 14980936
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with V(T) = 12 or 15 mL/kg ideal body weight, zero end‐expiratory pressure
Study: 14980936
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation with V(T) = 6 mL/kg ideal body weight, positive end‐expiratory pressure of 10 cm H(2)O
Study: 11446564
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg daily (n = 59)
Study: 9543191
Drug: Root-resective therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root-resective therapy with osseous recontouring and apically positioned flaps
Study: 3273486
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 micrograms in 5 ml sterile normal saline
Study: 7788195
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of saline
Study: 26171380
Drug: Medicine only
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine only
Study: 27798546
Drug: Corticosteroids at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids at the start of fluid therapy (group C)
Study: 27798546
Drug: Corticosteroids at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids at step 3 of treatment (group A)
Study: 27798546
Drug: Corticosteroids at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids at step 3 of treatment with adrenal stimulation test (group B)
Study: 25709044
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for antenatal depression and anxiety
Study: 24300755
Drug: Clarithromycin 25
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 25 mg daily for 6 months
Study: 24300755
Drug: Clarithromycin 25
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 25 mg daily for 3 months
Study: 24300755
Drug: Basal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal therapy with mometasone furoate 400 mcg daily
Study: 21972623
Drug: Indomethachin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethachin (25 mg orally, three times per day for 5 days)
Study: 11376303
Drug: Epoprostenol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol therapy (n = 201)
Study: 9834590
Drug: Thiamylal 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal 5 mg.kg‐1 with vecuronium 0.1 mg.kg‐1
Study: 9834590
Drug: Thiamylal 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal 3 mg.kg‐1 with additional thiamylal 4 mg.kg‐1 before intubation and vecuronium 0.1 mg.kg‐1
Study: 9834590
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg.kg‐1 with vecuronium 0.1 mg.kg‐1
Study: 7926305
Drug: Beta-hydroxybutyrate (BOHB)
Normalized name: L-alpha-amino-beta-hydroxybutyric acid
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-hydroxybutyrate (BOHB) infusion
Study: 2687006
Drug: Oxindanac 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxindanac 300 mg b.d.
Study: 2687006
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg b.d. with oxindanac
Study: 2687006
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg b.d. with placebo
Study: 20671100
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (standard of care)
Study: 28902073
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (among hrHPV+ women)
Study: 23483214
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group maintaining usual daily activity
Study: 21600129
Drug: Target Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Controlled Infusion (TCI) of propofol at an initial plasma concentration of 2.0 µg/ml, titrated upwards by 0.5 µg/ml steps until loss of consciousness
Study: 21600129
Drug: Manual Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Controlled Infusion (MCI) of propofol at 200 ml/h
Study: 21600129
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received an infusion of remifentanil
Study: 16420540
Drug: Glycerol cream
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol cream
Study: 16420540
Drug: Canola oil
Normalized name: Canola Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canola oil cream
Study: 16420540
Drug: Bisabolol cream
DrugBank: Levomenol (DB13153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bisabolol cream
Study: 16420540
Drug: Carbomer cream
DrugBank: Carbomer (DB15649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbomer cream
Study: 16420540
Drug: Basic cream
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic cream
Study: 16420540
Drug: IPP cream
Normalized name: IPPD
DrugBank: 4-(Isopropylamino)diphenylamine (DB14195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPP cream
Study: 12904840
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g) and vitamin D (800 units of cholecalciferol) only (group 1: n=35)
Study: 12904840
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D and nutritional supplement drink providing 300 Kcal, 12 g protein, 11.6 g fat, and 36.8 g carbohydrate per carton (group 2: n=36)
Study: 12904840
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D and nutritional supplement drink (group 2)
Study: 11309029
Drug: Bexarotene capsules
Normalized name: Bexarotene Capsules
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene capsules (300 mg/m2 per day)
Study: 11309029
Drug: Bexarotene gel
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bexarotene gel
Study: 2925967
Drug: Delayed Treatment
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Treatment (Control)
Study: 10442506
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg daily (doubled to 7.1 mg daily if diastolic blood pressure > 90 mmHg)
Study: 10442506
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg daily (doubled dosage if diastolic blood pressure > 90 mmHg)
Study: 7503838
Drug: Ibuprofen (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (with at least 70% compliance)
Study: 2217684
Drug: Amoxycillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (3 g) twice daily for 32 weeks
Study: 2217684
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 32 weeks
Study: 21513688
Drug: Very-low-dose naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-dose naltrexone (VLNTX) 0.125 or 0.250 mg/day
Study: 17679044
Drug: A/B antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/B antihypertensive agents
Study: 17679044
Drug: C/D antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/D antihypertensive agents
Study: 15385805
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (0.05, 0.5, 1.0, or 2.0 mg/kg)
Study: 11351767
Drug: Combined DTP-HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DTP-HBV vaccine
Study: 11351767
Drug: Separate DTP
Normalized name: DTP-348
DrugBank: DTP-348 (DB12741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate DTP and HBV vaccines
Study: 9562774
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of a questionnaire on the health of the elderly and introduction of the concept of activities of daily living
Study: 6315038
Drug: DAMME (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAMME (0.25 mg)
Study: 30877186
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg PF‐06372865
Study: 30877186
Drug: 52.5 mg
Normalized name: carbidopa 52.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52.5 mg PF‐06372865
Study: 24517906
Drug: Saline (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.2 mL)
Study: 22237063
Drug: Leptin (replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin (replacement doses)
Study: 22237063
Drug: Placebo (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice-daily injections)
Study: 12527321
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injections (0.1 ml of 0.9%, 2%, 4%, and 6% and 0.2 ml of 2% and 4%)
Study: 12527321
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 4% saline
Study: 12527321
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline injections)
Study: 8195851
Drug: Brodimoprim 200
Normalized name: brodimoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim 200 mg tablets (2 tablets on the first day, 1 tablet on following days)
Study: 8195851
Drug: Josamycin 500
Normalized name: josamycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin 500 mg tablets (3 tablets/day)
Study: 3515951
Drug: Single 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2 gm dose of cefotetan
Study: 3515951
Drug: Multidose cefoxitin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose cefoxitin (2 gm every 4 hours for three doses)
Study: 22103390
Drug: Palpation-guided arthrocentesis
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation-guided arthrocentesis with a conventional 20-mL syringe
Study: 22103390
Drug: US-guided arthrocentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided arthrocentesis with a 25-mL reciprocating procedure device (RPD) mechanical aspirating syringe
Study: 22103390
Drug: US-guided arthrocentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided arthrocentesis with a 60-mL automatic aspirating syringe
Study: 19067474
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 400 microg administered via a dry powder inhaler once daily in the evening (MF‐DPI 400 microg qd pm)
Study: 19067474
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered between 6 pm and 8 pm for 14 days
Study: 16045025
Drug: Isobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric bupivacaine (3.0 mL, 15 mg)
Study: 16045025
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (3.0 mL, 15 mg)
Study: 11896484
Drug: SSRIs (Selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (Selective Serotonin Reuptake Inhibitors)
Study: 8123997
Drug: bFGF (bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF (bovine fibroblast growth factor) administered intramuscularly at dosages of 0.4 or 0.28 microgram kg-1, once or twice a month, over 7-12 months
Study: 8123997
Drug: bFGF (bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF (bovine fibroblast growth factor) administered intramuscularly